EULAR 2020: Ixekizumab Improves Signs and Symptoms of PsA for Up to 3 Years
Subjects had responded inadequately to TNF inhibitors.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Subjects had responded inadequately to TNF inhibitors.
Only registered members have full access to PracticeUpdate content.